Skip to main content

Kendra Webb-Scott

Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S Press Release

Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S

KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced that it has enrolled the first patient…
Kendra Webb-Scott
September 3, 2024

https://www.clinicaltrialvanguard.com/executiveinterviews/surge-in-septic-shock-care-vivacelles-innovative-approach/
sepsis awareness month
Vivacelle Bio’s President and Chief Innovation Officer to Present Data Highlighting the Company’s Late-Stage Clinical Programs at the BIO International Convention 2024 EventsPress Release

Vivacelle Bio’s President and Chief Innovation Officer to Present Data Highlighting the Company’s Late-Stage Clinical Programs at the BIO International Convention 2024

Vivacelle is advancing a robust pipeline of therapies for shock and trauma-induced conditions Vivacelle's pipeline is led by VBI-S, a Phase 3-ready asset designated for the treatment of hypotension and…
Kendra Webb-Scott
May 31, 2024

Former Kansas City Chiefs Cheerleader Dies After Stillbirth

Sheds light on broader maternal healthcare issues for Black women.

https://21ninety.com/krystal-anderson-sepsis-death-stillbirth
Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients Press Release

Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients

KANSAS CITY, Mo., Feb. 29, 2024 /PRNewswire/ -- Today, researchers at Vivacelle Bio, Inc., a pioneering biotechnology company revealed the compelling outcomes of their phase 2a clinical trial of the…
Kendra Webb-Scott
February 29, 2024